Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-Mutant medullary thyroid cancer with extensive CNS metastases

Alexander Andreev-Drakhlin; Maria Cabanillas; Behrang Amini; Vivek Subbiah

doi:10.1200/PO.20.00096

Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-Mutant medullary thyroid cancer with extensive CNS metastases

Alexander Andreev-Drakhlin, Maria Cabanillas, Behrang Amini, Vivek Subbiah

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1302-1306
Number of pages	5
Journal	JCO Precision Oncology
Volume	4
DOIs	https://doi.org/10.1200/PO.20.00096
State	Published - 2020

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1200/PO.20.00096

Cite this

@article{a2ddcabd8e654f74b7621a8124182398,

title = "Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-Mutant medullary thyroid cancer with extensive CNS metastases",

author = "Alexander Andreev-Drakhlin and Maria Cabanillas and Behrang Amini and Vivek Subbiah",

note = "Funding Information: Supported by the National Cancer Institute (Grants No.T32 CA009666 [A.A.-D.] and CA016672). V.S. is supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA242845-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2020",

doi = "10.1200/PO.20.00096",

language = "English (US)",

volume = "4",

pages = "1302--1306",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-Mutant medullary thyroid cancer with extensive CNS metastases

AU - Andreev-Drakhlin, Alexander

AU - Cabanillas, Maria

AU - Amini, Behrang

AU - Subbiah, Vivek

N1 - Funding Information: Supported by the National Cancer Institute (Grants No.T32 CA009666 [A.A.-D.] and CA016672). V.S. is supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA242845-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85096339350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096339350&partnerID=8YFLogxK

U2 - 10.1200/PO.20.00096

DO - 10.1200/PO.20.00096

M3 - Article

C2 - 33154983

AN - SCOPUS:85096339350

SN - 2473-4284

VL - 4

SP - 1302

EP - 1306

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-Mutant medullary thyroid cancer with extensive CNS metastases

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this